Finally we have positive data in the treatment of breast cancer using ICI
International Conference on Oncology & Cancer Therapy
March 18-19, 2019 | London, UK
Celgene Corporation, USA
Keynote : J Med Oncl Ther
The idea of using the immune system to fight cancer is over 100 years old. (Paul Ehrlich’s “Magic Bullet”). A new molecular approach led to a better understanding of the immune system. Check point regulation, understanding roles of Tregs, Th1 and Th2, development of CAR-T cells, as well as regulation of DC and Macrophages, has led to discovery of immune checkpoint inhibitors (ICI) and modulators that are currently used in studies of several STs. Positive studies have led to the US FDA approval of a number of these compounds but none to date are approved in breast cancer (BrCa). Moreover, PD-1 / PDL-1, MSI high (and dMMR), MTB are the currently “best” predictive markers for IO therapy. BrCa actually has some of these markers positive only in subsets and less frequently expressed than most other tumors e.g. malignant melanoma or non-small cell lung cancer and others. In order to improve the potential efficacy of ICI in breast cancer, the addition of chemotherapy was one of the strategies. Many early and large clinical trials in all phases, are underway in BrCa and will be reported in 2018 and 2019. We will discuss the mechanism of action, its impact on BrCa and some of the early results and next generations ICI.
Stefan Glueck is the Vice President, Global Medical Affairs, at Celgene Corporation since October 2014, and a medical oncologist with focus on breast cancer. He has overseen oncology activities worldwide, as well as the Immuno-Oncology Program in solid tumors and hematology. Recently, his job requirements have shifted to include Early Assets. He was presented the “America’s Top Oncologists” 2008 award from Consumers’ Research Council of America, as well as “Best Doctors in America” honor since 2006 and has annually earned that prestige every year to 2014. This award was warranted after less than 3 years of working in the United States. He is a member of such prestigious professional organizations, as the American Society of Clinical Oncology, European Society for Medical Oncology, American & European Association of Cancer Research, and the International Association for Breast Cancer Research. He has authored or co-authored over 270 articles. In addition, he has written or co-written several book chapters and numerous journal abstracts and has presented more than 380 papers at national and international meetings.
E-mail: [email protected]